ELI LILLY & Co — Director's Dealing 2025

Feb 12, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ELI LILLY & Co (LLY)
CIK: 0000059478
Period of Report: 2025-02-10

Reporting Person: Skovronsky Daniel (EVP, CSO & Pres. LRL & LLY Imm)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-02-10	Common Stock	S	3950	$862.69	Disposed	118938.36	Direct
2025-02-10	Common Stock	S	340	$863.97	Disposed	118598.36	Direct
2025-02-10	Common Stock	S	710	$865.76	Disposed	117888.36	Direct
2025-02-10	Common Stock	A	18771.752	$868.88	Acquired	136660.112	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-02-10	Restricted Stock Unit	$	A	12684	Acquired	2026-02-01	Common Stock (12684)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	72359	Indirect
Common Stock	3257	Indirect

Footnotes

F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 11, 2024.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $862.49 to $863.27 (row 1), $863.57 to $864.45 (row 2), and $865.24 to $866.10 (row 3), respectively. The reporting person undertakes to provide to Eli Lilly and Company, any security holder of Eli Lilly and Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

F3: The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

F4: Each restricted stock unit represents a contingent right to receive one share of Eli Lilly and Company common stock.